ClinicalTrials.gg
CompletedNCT00950911Updated Feb 11, 2014Results posted

Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only

A Phase 3 interventional study of amg 162 in Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer and Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma, sponsored by Amgen. Completed at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-11.

Sponsored by Amgen · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Multiple Myeloma by Amgen — none open to participants now, none under way, none of them phase 3. Multiple Myeloma · Amgen.

Enrollment
30th of 40
35 · median 101
Started
2009
with 2 others
Phase 3
11 of 43
none open now
Registered
13th of 43
by date

Among the 43 studies in Multiple Myeloma by Amgen, this one is the 30th largest by enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2009, is one of 11 in phase 3, and was the 13th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

None of the 43 studies in Multiple Myeloma by Amgen is open now. The open studies under Multiple Myeloma, anywhere →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 43 studies in Multiple Myeloma by Amgen as a file.
02

Study summary

The purpose of this study is to describe the safety and tolerability of denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received either zoledronic acid (Zometa®) or denosumab.

03

Conditions studied

  • Bone Metastases in Men With Hormone-Refractory Prostate Cancer
  • Bone Metastases in Subjects With Advanced Breast Cancer
  • Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma

Keywords

  • Bone metastases
  • Hormone-refractory prostate cancer
  • Multiple myeloma
  • Denosumab
  • Breast cancer
  • 20050103
  • 20050136
  • 20050244
  • Advanced cancer
  • Tumor
  • Prostate cancer
  • Zoledronic acid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects currently enrolled in study 20050103, 20050136, or 20050244
  • Subjects must sign the before any study specific procedures are performed

Exclusion criteria

Exclusion Criteria:

  • Developed sensitivity to mammalian cell derived drug products during the 20050103, 20050136, or 20050244 study
  • Currently receiving any unapproved product other than denosumab
  • Subject is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment
  • Subject (male or female) is not willing to use 2 highly effective during treatment and for 7 months (women) or 10 months (men) after the end of treatment
  • Male subject with a pregnant partner who is not willing to use a condom during treatment and for additional 10 months after the end of treatment
  • Any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written and/or comply with study procedures
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    1

    Drug: amg 162

Interventions

  • 120 mg SC injection of denosumab Q4W until the subject has access to commercially available product or for up to 2 years, which ever comes first.

06

What researchers measure

Primary outcomes

  1. Number of Participants Survived

    Time frame: 2 years

07

Results

Posted Feb 11, 2014

Participant flow

Subjects recuited in this open-label extension study were those who were enrolled in the 2 parent (phase 3, randomized, double-blind, active-controlled) studies 20050103 (NCT00321620) or 20050136 (NCT00321464) at sites in the Czech Republic and United Kingdom.

Participant flow — Overall Study
MilestoneZoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4WDenosumab 120 mg Q4W / Denosumab 120 mg Q4W
Started1718
Completed53
Not completed1215
Withdrew: Adverse event02
Withdrew: Death46
Withdrew: Disease progression22
Withdrew: Consent withdrawn13
Withdrew: Administrative decision31
Withdrew: Ineligibility determined10
Withdrew: Noncompliance10
Withdrew: Poor performance status01

Outcome measures

PrimaryNumber of Participants Survived
Time frame:
2 years
Reported as:
Number · Participants
Number of Participants Survived
ParticipantsZoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4WDenosumab 120 mg Q4W / Denosumab 120 mg Q4W
Number of Participants Survived1312

Adverse events

Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4W—8/17 (47.1%)13/17 (76.5%)
Denosumab 120 mg Q4W / Denosumab 120 mg Q4W—10/18 (55.6%)13/18 (72.2%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventZoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4WDenosumab 120 mg Q4W / Denosumab 120 mg Q4W
Osteonecrosis of jawMusculoskeletal and connective tissue disorders2/171/18
CachexiaMetabolism and nutrition disorders1/172/18
Atrial fibrillationCardiac disorders1/170/18
Cardiac failureCardiac disorders1/170/18
DeathGeneral disorders1/170/18
ConvulsionNervous system disorders1/170/18
Hip arthroplastySurgical and medical procedures1/170/18
Jugular vein thrombosisVascular disorders1/170/18
AnaemiaBlood and lymphatic system disorders0/171/18
DiarrhoeaGastrointestinal disorders0/171/18
Most frequent other events
Showing 10 of 137
Most frequent other events
EventZoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4WDenosumab 120 mg Q4W / Denosumab 120 mg Q4W
AnaemiaBlood and lymphatic system disorders1/176/18
FatigueGeneral disorders3/176/18
NauseaGastrointestinal disorders1/175/18
ArthralgiaMusculoskeletal and connective tissue disorders4/170/18
ConstipationGastrointestinal disorders0/174/18
Decreased appetiteMetabolism and nutrition disorders1/174/18
Back painMusculoskeletal and connective tissue disorders2/174/18
NeutropeniaBlood and lymphatic system disorders3/171/18
Bone painMusculoskeletal and connective tissue disorders3/172/18
VomitingGastrointestinal disorders2/173/18

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Zoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4WDenosumab 120 mg Q4W / Denosumab 120 mg Q4WTotal
Mean61.6 ± 11.161.1 ± 13.061.3 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)Zoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4WDenosumab 120 mg Q4W / Denosumab 120 mg Q4WTotal
Female7613
Male101222
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Zoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4WDenosumab 120 mg Q4W / Denosumab 120 mg Q4WTotal
White or Caucasian171734
Black or African American011
08

Study locations

17 sites
  • Research Site
    Jindrichuv Hradec, 377 01, Czech Republic
  • Research Site
    Kromeriz, 767 55, Czech Republic
  • Research Site
    Olomouc, 775 20, Czech Republic
  • Research Site
    Praha 1, 110 00, Czech Republic
  • Research Site
    Praha 4, 140 00, Czech Republic
  • Research Site
    Praha 4, 140 44, Czech Republic
  • Research Site
    Praha 5, 150 06, Czech Republic
  • Research Site
    Praha 6, 160 00, Czech Republic
  • Research Site
    Zlin, 762 75, Czech Republic
  • Research Site
    Chichester, PO19 4SE, United Kingdom
  • Research Site
    Leeds, LS9 7TF, United Kingdom
  • Research Site
    London, SE1 9RT, United Kingdom
  • Research Site
    London, W2 1NY, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom
  • Research Site
    Northwood, HA6 2RN, United Kingdom
  • Research Site
    Peterborough, PE3 9GZ, United Kingdom
  • Research Site
    York, YO31 8HE, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Feb 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2009
First posted
Aug 3, 2009
Start
Jul 2009
Primary completionActual
Feb 2012
CompletionActual
Apr 2012
Results first posted
Feb 11, 2014
Last update
Feb 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00950911
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 3, 2009
Start date
Jul 2009
Primary completion
Feb 2012
Completion
Apr 2012
Results posted
Feb 11, 2014
Last update
Feb 11, 2014

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion